Trial ID: | L4837 |
Source ID: | NCT00422955
|
Associated Drug: |
Rosiglitazone
|
Title: |
Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.
|
Acronym: |
|
Status: |
COMPLETED
|
Study Results: |
NO
|
Results: |
|
Conditions: |
Neuropathy, Diabetic
|
Interventions: |
DRUG: rosiglitazone
|
Outcome Measures: |
Primary: Change in transcapillary escape rate of L125 albumin following 16 weeks treatment | Secondary: Change in plasma volume, pedal oedema, extracellular fluid volume following 16 weeks treatment.
|
Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE3
|
Enrollment: |
36
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
Start Date: |
2003-11
|
Completion Date: |
2005-10
|
Results First Posted: |
|
Last Update Posted: |
2016-09-15
|
Locations: |
GSK Investigational Site, Nijmegen, 6525 EZ, Netherlands
|
URL: |
https://clinicaltrials.gov/show/NCT00422955
|